Keith Brecher, MD
Neurology · Warwick, RINPI 1568457323
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 30.3% of the total. 2025 is the largest year on record at $941, 5.0 times the $189 reported in 2019.
Across 207 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pfizer$334
- Lundbeck LLC$280
- EMD Serono, Inc.$253
- Lilly USA, LLC$237
- SK Life Science, Inc.$200
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,697100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 74 | $1,120 |
| Pfizer | 21 | $334 |
| Lundbeck LLC | 11 | $280 |
| EMD Serono, Inc. | 12 | $253 |
| Lilly USA, LLC | 13 | $237 |
| SK Life Science, Inc. | 9 | $200 |
| Sumitomo Pharma America, Inc. | 9 | $197 |
| Novartis | 12 | $193 |
| Amgen(2 entities) | 6 | $109 |
| UCB, Inc. | 4 | $99 |
| Axsome Therapeutics, Inc. | 4 | $73 |
| AstraZeneca | 3 | $63 |
| Eisai Inc. | 4 | $57 |
| Neurelis, Inc. | 3 | $47 |
| Vanda Pharmaceuticals Inc. | 2 | $47 |
| Teva Pharmaceuticals USA, Inc. | 3 | $44 |
| Adamas Pharmaceuticals, Inc. | 2 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $42 |
| Biohaven Pharmaceuticals, Inc. | 2 | $41 |
| Biogen | 2 | $36 |
| MDD US Operations, LLC | 1 | $31 |
| Jazz Pharmaceuticals Inc. | 1 | $29 |
| Mallinckrodt Enterprises LLC | 1 | $25 |
| Sanofi | 1 | $23 |
| Impel Pharmaceuticals Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Assertio Therapeutics, Inc. | 1 | $16 |
How this compares
$3,697 in reported general payments places this provider in the 70th percentile of 86 neurology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 26 | $189,968 |
| Droxidopa | 12 | $106,466 |
| AptiomEslicarbazepine Acetate | 27 | $49,795 |
| Nurtec OdtRimegepant Sulfate | 28 | $37,006 |
| QuliptaAtogepant | 27 | $30,330 |
| Xtampza ErOxycodone Myristate | 12 | $21,030 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 24 | $20,963 |
| UbrelvyUbrogepant | 19 | $19,609 |
| Emgality PenGalcanezumab-Gnlm | 26 | $19,592 |
| RexultiBrexpiprazole | 12 | $19,296 |
| Levetiracetam | 431 | $14,354 |
| Lacosamide | 80 | $12,784 |
| Pregabalin | 376 | $9,167 |
| LyricaPregabalin | 11 | $8,333 |
| Gabapentin | 362 | $7,614 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt, Lyrica, Dilantin | $334 | $50,32976 claims |
| AbbVieQulipta, Ubrelvy | $1,120 | $49,93946 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $18 | $19,29612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 86 neurology providers in Rhode Island.
Other neurology in Warwick
- Arshad IqbalWarwick$21K
- Gary LeuropaWarwick$7K
- Adam DrobnisWarwick$4K
- Mauricio VillamarWarwick$798
- Stephen SallowayProvidence$329K
- Peter BellafioreWakefield$274K
- Norman GordonEast Providence$206K
- Syed RizviProvidence$160K
- Albert MaranoJohnston$145K
- John EastonProvidence$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.